{"title":"Promising immunotherapeutic approaches for primary effusion lymphoma.","authors":"Jutatip Panaampon, Seiji Okada","doi":"10.37349/etat.2024.00242","DOIUrl":null,"url":null,"abstract":"<p><p>Primary effusion lymphoma (PEL) is a large B-cell neoplasm usually presenting as a serious effusion in body cavities without detectable tumor masses. It is an AIDS-related non-Hodgkin's lymphoma (HL) with human herpes virus 8 (HHV8)/Kaposi sarcoma-associated herpes virus (KSHV) infection. A combination antiretroviral therapy (cART) prolongs the lifespan of AIDS and AIDS-related malignant lymphoma patients, but PEL continues to have a dismal prognosis. PEL showed disappointing outcomes with standard chemotherapy such as CHOP or CHOP-like regimens. A PEL status highlights the urgent need for new therapeutic approaches and treatment strategies and improve clinical outcomes. This review discusses the current knowledge and some recent clinical trials for PEL in the platform of immunotherapy as well as promising future immunotherapeutic approaches for PEL.</p>","PeriodicalId":73002,"journal":{"name":"Exploration of targeted anti-tumor therapy","volume":"5 3","pages":"699-713"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11220309/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Exploration of targeted anti-tumor therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37349/etat.2024.00242","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Primary effusion lymphoma (PEL) is a large B-cell neoplasm usually presenting as a serious effusion in body cavities without detectable tumor masses. It is an AIDS-related non-Hodgkin's lymphoma (HL) with human herpes virus 8 (HHV8)/Kaposi sarcoma-associated herpes virus (KSHV) infection. A combination antiretroviral therapy (cART) prolongs the lifespan of AIDS and AIDS-related malignant lymphoma patients, but PEL continues to have a dismal prognosis. PEL showed disappointing outcomes with standard chemotherapy such as CHOP or CHOP-like regimens. A PEL status highlights the urgent need for new therapeutic approaches and treatment strategies and improve clinical outcomes. This review discusses the current knowledge and some recent clinical trials for PEL in the platform of immunotherapy as well as promising future immunotherapeutic approaches for PEL.
原发性渗出性淋巴瘤（PEL）是一种大B细胞肿瘤，通常表现为体腔内严重渗出，但无法检测到肿瘤肿块。它是一种与艾滋病相关的非霍奇金淋巴瘤（HL），伴有人类疱疹病毒8（HHV8）/卡波西肉瘤相关疱疹病毒（KSHV）感染。抗逆转录病毒联合疗法（cART）可延长艾滋病和艾滋病相关恶性淋巴瘤患者的寿命，但PEL的预后仍然不容乐观。PEL采用标准化疗（如CHOP或类似CHOP的方案）的疗效令人失望。PEL的现状凸显了对新治疗方法和治疗策略的迫切需求，以及对改善临床预后的迫切需求。本综述讨论了免疫疗法平台中 PEL 的现有知识和一些最新临床试验，以及未来有望用于 PEL 的免疫疗法。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
